Calypte Biomedical to Announce Third Quarter 2002 Financial Results On October 24th.Business Editors ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 16, 2002 Calypte Biomedical Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CALY) announced it will host a conference call on Thursday, October 24, at 8:00 a.m. (PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT ), 11:00 a.m. (EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) to discuss its third quarter 2002 financial results. Investors in the U.S. and Canada interested in participating in the conference call may dial 888/747-3510 and reference the Calypte Biomedical call. International investors may dial 703/871-3085. Calypte recommends dialing into the call approximately 10 minutes prior to the scheduled start time. Investors will have the opportunity to listen to a live Webcast of the conference call via the Internet at the Investors section of the company's website at www.calypte.com. If you are unable to participate in the call a replay will be available through October 26, 2002 by calling 888/266-2081. International callers should dial 703/925-2533 for the replay. The replay confirmation code is 6262603. The Webcast will be archived on the Investor section of the Company's website: www.calypte.com. About Calypte Biomedical: Calypte Biomedical Corporation is dedicated to the development and commercialization of urine-based diagnostic products and services for the Human Immunodeficiency Virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. Type 1 (HIV-1), sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely and other infectious diseases. Calypte's tests include the screening EIA (Electronic Industries Alliance, Arlington, VA, www.eia.org) A membership organization founded in 1924 as the Radio Manufacturing Association. It sets standards for consumer products and electronic components. and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-based tests, the Company's testing algorithms are non-invasive, easier to use, less expensive and have significantly less risk than blood-based testing, and they have 99.7% sensitivity in subjects previously identified as HIV-1 infected and 100% specificity in subjects at low risk when combined with the urine-based Western Blot supplemental test. The company believes that accurate, non-invasive urine-based testing methods for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion